Big Pharma and CAR-T: Testing the water or in at the deep end?
Following Novartis and Gilead’s success, others are “scrambling to build up their T-Cell capabilities,” say venture capitalists. We look at where Big Pharma stands in this blossoming sector. Big Pharma firms will be looking at strategies to enter the chimeric antigen receptor (CAR) T-cell s ...
Culture Biosciences has secured $5.5 million in funding. Founded by former Google X engineers, the CDMO has harnessed drone delivery technology t ...
“We can produce the volume we need with more limited manufacturing capacity,” says AstraZeneca in the wake of closing two biologics facilitie ...
Following a strong year for its manufacturing services division, Charles River Laboratories intends to invest further to benefit from the high gr ...
Vor Biopharma, founded by PureTech, has raised $42 million to support its hematopoietic stem cell (HSC)-based candidate through Series A financin ...
Recent Tweets
-
RT @Dan5tanton: “We can produce the volume we need with more limited manufacturing capacity,” says #AstraZeneca in the wake of clos… https://t.co/t4kgnPc669
5 hours ago
-
RT @Dan5tanton: Following Novartis and Gilead’s success, others are “scrambling to build up their T-Cell capabilities,” say venture… https://t.co/7zJuWL0uGN
2 days ago
-
#CDMO WuXi Biologics will harness its growing global network to supply the commercial drug substance and product fo… https://t.co/zpkjaCQqsS
2 days ago
-
RT @Dan5tanton: Regeneron has applied to build a three-storey facility as part of a reported €200 million expansion at its Limerick… https://t.co/UDjsU930ze
1 week ago
Trending
2019
Biosimilars: Challenging the Justifications for Clinical Testing
Manufacturing
The Changing Landscape of Single Use in Bioprocessing: An Interview with Stefan Schlack and Jean-Marc Cappia
Business
Trends in Real-World Study Design and Postmarketing Commitments in the EU and US: What We Can Learn from Big Data
Analytical
Qualitative and Quantitative Host Cell Protein Analysis Using Mass Spectrometry